In this context, a novel therapy based on the combination of the oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L and the anti-PD-1 mAb Pembrolizumab has been tested by Garofalo et al., in vitro and in a mesothelioma mouse model. Here, PDCD1 is linked to mesothelioma.